Search
Sihuan Pharmaceutical's share price surged during the midday trading session, fueled by a supportive policy issued by the National Healthcare Security Administration and the National Health Commission aimed at fostering the development of innovative drugs. This policy seeks to explore the opening up of medical insurance data resources and establish a catalogue of innovative drugs eligible for commercial health insurance coverage. According to a research report by Ping An Securities, China's innovative pharmaceutical enterprises are effectively reshaping the global pharmaceutical innovation landscape, with several products generating revenues exceeding US$1 billion. Bolstered by both policy incentives and commercial advancements, the innovative drug industry is poised for a promising future.
-
C114 Communication Network -
Communication Home
